DE69511379D1 - Immunogens gegen gonadotropin releasing hormone - Google Patents

Immunogens gegen gonadotropin releasing hormone

Info

Publication number
DE69511379D1
DE69511379D1 DE69511379T DE69511379T DE69511379D1 DE 69511379 D1 DE69511379 D1 DE 69511379D1 DE 69511379 T DE69511379 T DE 69511379T DE 69511379 T DE69511379 T DE 69511379T DE 69511379 D1 DE69511379 D1 DE 69511379D1
Authority
DE
Germany
Prior art keywords
gegen
immunogens
releasing hormone
gonadotropin releasing
immunogenic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69511379T
Other languages
German (de)
Other versions
DE69511379T2 (en
Inventor
Stephen Grimes
Robert Scibienski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aphton Corp
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphton Corp filed Critical Aphton Corp
Publication of DE69511379D1 publication Critical patent/DE69511379D1/en
Application granted granted Critical
Publication of DE69511379T2 publication Critical patent/DE69511379T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/854—Glands
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Abstract

Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.
DE69511379T 1994-01-27 1995-01-26 IMMUNOGENS AGAINST GONADOTROPIN RELEASING HORMONE Expired - Fee Related DE69511379T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/188,223 US5688506A (en) 1994-01-27 1994-01-27 Immunogens against gonadotropin releasing hormone
PCT/US1995/001225 WO1995020600A1 (en) 1994-01-27 1995-01-26 Immunogens against gonadotropin releasing hormone

Publications (2)

Publication Number Publication Date
DE69511379D1 true DE69511379D1 (en) 1999-09-16
DE69511379T2 DE69511379T2 (en) 1999-11-25

Family

ID=22692254

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69511379T Expired - Fee Related DE69511379T2 (en) 1994-01-27 1995-01-26 IMMUNOGENS AGAINST GONADOTROPIN RELEASING HORMONE

Country Status (10)

Country Link
US (3) US5688506A (en)
EP (1) EP0741744B1 (en)
JP (1) JP3477713B2 (en)
AT (1) ATE183198T1 (en)
AU (1) AU698738B2 (en)
DE (1) DE69511379T2 (en)
DK (1) DK0741744T3 (en)
ES (1) ES2137498T3 (en)
GR (1) GR3031716T3 (en)
WO (1) WO1995020600A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030617A (en) * 1993-01-12 2000-02-29 The Johns Hopkins University School Of Medicine Use of growth differentiation factor-9 (GDF-9) to inhibit oocyte maturation
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
ES2361474T3 (en) * 1996-02-08 2011-06-17 Cancer Advances, Inc. IMMUNE PROCEDURES FOR THE TREATMENT OF GASTROINTESTINAL CANCER.
CN1170593C (en) * 1997-05-12 2004-10-13 埃弗顿有限公司 Immunogenic compsns to CCK-b/gastrin-receptor and methods for treatment of tumors
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US20030068326A1 (en) * 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
JP2002515458A (en) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン Prevention and treatment of hypergastrinemia
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US20020058040A1 (en) * 1999-12-23 2002-05-16 Stephen Grimes Stable immunogenic composition for frozen storage
US6783761B2 (en) * 2000-05-05 2004-08-31 Aphton Corporation Chimeric peptide immunogens
ATE534401T1 (en) 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa VACCINES CONTAINING MAGE ANTIGEN COUPLED TO A PROTEIN D FRAGMENT
AU2002246758A1 (en) 2000-12-29 2002-07-16 Vanderbilt University Epididymal lipocalin gene and uses thereof
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US6810583B2 (en) * 2001-08-07 2004-11-02 International Business Machines Corporation Coupling of conductive vias to complex power-signal substructures
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
EP1528915A2 (en) * 2002-07-03 2005-05-11 Aphton Corporation Liposomal vaccine
CA2520010C (en) * 2003-03-28 2012-07-10 Aphton Corporation Gastrin hormone immunoassays
EP1684782B1 (en) 2003-10-03 2015-09-30 Thorn BioScience, LLC Process for the synchronization of ovulation for timed breeding without heat detection
CA2564562A1 (en) 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use
WO2005120552A1 (en) * 2004-06-11 2005-12-22 Ym Biosciences Inc. METHODS AND FORMULATIONS OF GnRH/LEUKOTOXIN CHIMERAS FOR TESTOSTERONE SUPPRESSION
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
EP2010569A4 (en) 2006-03-20 2009-09-09 Xoma Technology Ltd Human antibodies specific for gastrin materials and methods
JP5452223B2 (en) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション IAP inhibitor
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TR201807756T4 (en) 2006-09-26 2018-06-21 Infectious Disease Res Inst Vaccine composition containing synthetic adjuvant.
SI2086582T1 (en) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
EA015817B1 (en) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Immunogenic composition comprising an oil in water emulsion adjuvant
AR066676A1 (en) 2007-05-24 2009-09-02 Glaxosmithkline Biolog Sa ANTIGENIC LIOFILIZED COMPOSITION CONTAINING A TOLL TYPE RECEIVER AGONIST
EP2072060A1 (en) 2007-12-18 2009-06-24 Institut Curie Methods and compositions for the preparation and use of toxin conjugates.
CA2739318A1 (en) * 2008-08-07 2010-02-11 Mercia Pharma, Llc Immunotherapeutic compositions for the treatment of alzheimer's disease
CU23739A1 (en) 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION USING COMBINATIONS OF VARIANTS OF THE GONADOTROPIN LIBERATING HORMONE (GNRH) AS IMMUNOGEN
US8905913B2 (en) 2009-04-23 2014-12-09 Jbs United Animal Health Ii Llc Method and composition for synchronizing time of insemination
MX2011012836A (en) 2009-06-05 2012-04-20 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants.
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2675473A1 (en) 2011-02-15 2013-12-25 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
MX350795B (en) 2011-04-08 2017-09-19 Inmune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses.
GB201121571D0 (en) 2011-12-15 2012-01-25 Astrimmune Ltd Compounds and uses thereof
ES2729967T3 (en) 2012-02-07 2019-11-07 Infectious Disease Res Inst Enhanced adjuvant formulations comprising TLR4 agonists and methods for using them
ES2673556T3 (en) 2012-05-16 2018-06-22 Immune Design Corp. Vaccines for HSV-2
US9770011B2 (en) 2012-09-29 2017-09-26 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
CN113398243A (en) 2012-11-28 2021-09-17 联合动物健康第二有限责任公司 Method for synchronizing insemination times of gilts
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR102411781B1 (en) 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Single vial vaccine formulations
EP3169352A1 (en) 2014-07-15 2017-05-24 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
EP3443123B1 (en) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
JP7195148B2 (en) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Formulation containing TLR agonist and method of use
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
KR20220165789A (en) 2016-06-01 2022-12-15 액세스 투 어드밴스드 헬스 인스티튜트 Nanoalum particles containing sizing agent
EP3624841A4 (en) 2017-06-15 2021-01-27 Cancer Advances, Inc., Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
KR20200028395A (en) 2017-06-15 2020-03-16 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Nanostructured lipid carriers and stable emulsions and their use
KR20200066309A (en) 2017-09-08 2020-06-09 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Liposomal formulations containing saponins and methods of use
KR20220125149A (en) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 Compositions and methods for spray drying adjuvant vaccine emulsions
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
US20240050561A1 (en) 2020-12-23 2024-02-15 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4201770A (en) * 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
US4618598A (en) * 1982-04-12 1986-10-21 Duke University Method of regulating hormone function or release
US4879112A (en) * 1984-02-07 1989-11-07 University Of Saskatchewan Monoclonal antibodies agaisnt GnRH
US4676981A (en) * 1984-02-07 1987-06-30 University Of Saskatchewan Monoclonal antibodies against GnRH
US4608251A (en) * 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
AU5359186A (en) * 1985-01-25 1986-08-13 Population Council, Inc., The Method & product for enhancing circulating antibody response
US4740500A (en) * 1985-01-31 1988-04-26 The Salk Institute For Biological Studies GnRH antagonists VIII
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
AU5993186A (en) * 1985-06-04 1987-01-07 Biotechnology Research Partners Limited Autoantigen vaccines
CA1239346A (en) * 1985-06-04 1988-07-19 Gursaran P. Talwar Birth control vaccine
FR2593705B1 (en) 1986-02-04 1991-07-26 Lafon Labor COMPOSITION FOR THE INTERRUPTION OF PREGNANCY COMPRISING MONOCLONAL ANTIBODIES RECOGNIZING THE CHORIONIC HORMONE GONADOTROPIC OR A PEPTIDE OF ANALOGUE STRUCTURE, MONOCLONAL ANTIBODIES, PROCESS FOR THE PRODUCTION OF SUCH ANTIBODIES, HYBRIDOMA AND METHOD OF OBTAINING
US4795634A (en) * 1986-03-14 1989-01-03 Aphton Corporation Method for contraception by immunization against the zona pellucida
NZ220932A (en) * 1986-07-03 1990-05-28 Victoria State Composition comprising an antigenic substance, such as lhrh, conjugated to at least two different carriers and method of immunological castration and spaying
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
US4975420A (en) * 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
FR2623715B1 (en) 1987-11-26 1990-12-21 Lafon Labor PEPTIDE STRUCTURES, IMMUNOGENS CONTAINING THEM AND THEIR APPLICATIONS IN FERTILITY CONTROL
JPH03502584A (en) * 1988-08-30 1991-06-13 アプライド・リサーチ・システムス・エー・アール・エス・ホールディング・エヌ・ブイ Recombinant fusion proteins that alter hormone secretion
US5036047A (en) * 1988-09-29 1991-07-30 Pitman-Moore, Inc. Method and composition for preventing conception
US5661126A (en) * 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
EP0380230B1 (en) * 1989-01-24 1994-11-17 Aphton Corporation Immunogenic compositions against gastrin peptides
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
WO1990009799A1 (en) 1989-02-23 1990-09-07 Colorado State University Research Foundation GnRH ANALOGS FOR DESTROYING GONADOTROPHS
US5484592A (en) * 1989-03-23 1996-01-16 Stitching Centraal Diergeneeskundig Instituut Peptide, immunogenic composition and vaccine or medicinal preparation: a method of immunising a mammal against LHRH, and a method of improving the meat quality of pigs
NZ235038A (en) * 1989-08-25 1992-09-25 Biotech Australia Pty Ltd Outermembrane lipoprotein (tratp)/lhrh fusion protein and its use in immunological castration or reproductive inhibition
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
DE4003944A1 (en) 1990-02-14 1991-08-22 Gerhard Dr Prinzhaus New synthetic polypeptide conjugate of LHRH and keyhole limpet haemocy - used to provide antibodies to hormone, for treating breast and prostate carcinoma etc.
FR2661180B1 (en) 1990-04-23 1995-04-28 Inst Nat Sante Rech Med (HYDROXYPROLINE 9) LHRH, ITS PROCESS FOR OBTAINING AND APPLYING AS A MEDICINE.
US5648340A (en) * 1991-10-31 1997-07-15 Barnea; Eytan R. Gestational agents for controlling cell proliferation
US5324512A (en) * 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
GB9100468D0 (en) * 1991-01-09 1991-02-20 Proteus Molecular Design Improvements in and relating to hormones
NL9100151A (en) * 1991-01-29 1992-08-17 Instituut Voor Veeteeltkundig METHOD FOR COMPLETELY C.Q. ALMOST COMPLETELY ELIMINATE THE "BEREGEUR" OF MEAT FROM REARED MALE PIGS BY IMMUNIZING THE MALE PIGS AGAINST THE GNRH HORMONE WHILE REARING.
KR100257214B1 (en) * 1991-03-01 2000-05-15 데스꼴롱그 티에리 Method of enhancing organoleptic properties of non-castrated males meat of domestic animals
AU634379B2 (en) * 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
US5262521A (en) * 1991-06-07 1993-11-16 Sri International Isolated atrial peptide-degrading enzyme and novel compounds useful as inhibitors thereof
EP0592512A1 (en) * 1991-07-01 1994-04-20 University Technologies International Inc. (Uti) NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS
US5955080A (en) * 1991-07-26 1999-09-21 Commonwealth Scientific And Industrial Research Organisation Self-adjuvanting peptide vaccine delivery system and production thereof
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
WO1993008290A1 (en) 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
DK0647275T3 (en) * 1992-06-23 2005-01-24 Sinai School Medicine Cloning and expression of the gonatotropin-releasing hormone receptor
US5557033A (en) * 1992-09-22 1996-09-17 Regents Of The University Of Minnesota Method of increasing egg production in avian species by active immunization against vasoactive intestinal peptide
FR2700855B1 (en) * 1993-01-28 1995-03-03 Commissariat Energie Atomique Immunometric determination of an antigen or a hapten.
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
DE69431114T2 (en) * 1993-04-27 2003-03-13 United Biomedical Inc IMMUNOGENEOUS LHRH PEPTIDE CONSTRUCTION AND SYNTHETIC, UNIVERSAL IMMUNE STIMULATORS AS VACCINE
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5508383A (en) * 1994-03-09 1996-04-16 Tap Holdings Inc. Cyclic peptide LHRH antagonists
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
CA2163325A1 (en) * 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use
AU7718696A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Pseudomonas exotoxin as immunogenic carrier in synthetic conjugate vaccines
WO1997015316A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone

Also Published As

Publication number Publication date
JPH09508391A (en) 1997-08-26
JP3477713B2 (en) 2003-12-10
EP0741744A1 (en) 1996-11-13
AU698738B2 (en) 1998-11-05
US6132720A (en) 2000-10-17
AU1737195A (en) 1995-08-15
EP0741744B1 (en) 1999-08-11
US6303123B1 (en) 2001-10-16
ATE183198T1 (en) 1999-08-15
ES2137498T3 (en) 1999-12-16
GR3031716T3 (en) 2000-02-29
WO1995020600A1 (en) 1995-08-03
DE69511379T2 (en) 1999-11-25
DK0741744T3 (en) 1999-12-06
US5688506A (en) 1997-11-18

Similar Documents

Publication Publication Date Title
DE69511379D1 (en) Immunogens gegen gonadotropin releasing hormone
CA2161445A1 (en) Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (en) Antagonists of gonadotropin releasing hormone.
MX9700534A (en) Use of droloxifene for the treatment of prostatic diseases, endometriosis and obesity.
MD1920F2 (en) Composititon and method of prevention and delay of the Alzheimer's disease origin
TJ242B (en) A method of treatment an ovarian estrogen dependent condition
MX9101784A (en) TRANSDERMAL CONTRACEPTIVE FORMULATIONS, METHODS AND DEVICES
PT771147E (en) Compositions and methods for enhanced tumor cell immunity in vivo
MX9804395A (en) Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen.
BG103170A (en) Polymorphic form ii of finasteride and method for its preparation
CA2252604A1 (en) Methods of treating type i hypersensitivity using monophosphoryl lipid a
MY116128A (en) Vaccine composition
EP0282343A3 (en) Method to stimulate the immune response to specific antigens
AU3991899A (en) Verotoxin b subunit for immunization
MY128929A (en) Vaccine against hepatitis a and hepatitis b
DE69711773T2 (en) OVULATION RELEASING MEDICINAL PRODUCTS CONTAINING LUTEINIZING HORMONE
AU8934898A (en) Use of droloxifene for the treatment of prostatic diseases endometriosis and obesity
IL132718A0 (en) Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors
BG101173A (en) Vaccine against pasteurellosis and haemorrhagic disease in rabbits
MX9705082A (en) Compositions for the delivery of antigens.
BG51699A1 (en) Stimulating fertility agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee